Enteric-coated mycophenolate sodium (Myfortic) + Cyclosporine (Neoral) + Prednisone
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Kidney Transplantation
Conditions
Kidney Transplantation
Trial Timeline
Dec 1, 2006 → Jun 1, 2009
NCT ID
NCT00419926About Enteric-coated mycophenolate sodium (Myfortic) + Cyclosporine (Neoral) + Prednisone
Enteric-coated mycophenolate sodium (Myfortic) + Cyclosporine (Neoral) + Prednisone is a approved stage product being developed by Novartis for Kidney Transplantation. The current trial status is completed. This product is registered under clinical trial identifier NCT00419926. Target conditions include Kidney Transplantation.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00419926 | Approved | Completed |
Competing Products
20 competing products in Kidney Transplantation